DE10063435A1 - Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung - Google Patents

Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Info

Publication number
DE10063435A1
DE10063435A1 DE10063435A DE10063435A DE10063435A1 DE 10063435 A1 DE10063435 A1 DE 10063435A1 DE 10063435 A DE10063435 A DE 10063435A DE 10063435 A DE10063435 A DE 10063435A DE 10063435 A1 DE10063435 A1 DE 10063435A1
Authority
DE
Germany
Prior art keywords
amino
quinazoline
oxo
buten
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE10063435A
Other languages
German (de)
English (en)
Inventor
Frank Himmelsbach
Elke Langkopf
Stefan Blech
Birgit Jung
Anke Baum
Flavio Solca
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim Pharma GmbH and Co KG
Original Assignee
Boehringer Ingelheim Pharma GmbH and Co KG
Boehringer Ingelheim Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7667887&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE10063435(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Pharma GmbH and Co KG, Boehringer Ingelheim Pharmaceuticals Inc filed Critical Boehringer Ingelheim Pharma GmbH and Co KG
Priority to DE10063435A priority Critical patent/DE10063435A1/de
Priority to EP01271363.2A priority patent/EP1345910B9/de
Priority to EP09158964A priority patent/EP2112140A1/de
Priority to YUP-496/03A priority patent/RS50860B/sr
Priority to EA200300671A priority patent/EA006317B1/ru
Priority to HK04103590.4A priority patent/HK1060571B/xx
Priority to DE50114874T priority patent/DE50114874D1/de
Priority to AU1917402A priority patent/AU1917402A/xx
Priority to BRPI0116266A priority patent/BRPI0116266B8/pt
Priority to MEP-2008-595A priority patent/ME02777B/me
Priority to HR20030504A priority patent/HRP20030504B1/xx
Priority to ES01271363T priority patent/ES2326617T3/es
Priority to JP2002551540A priority patent/JP3827641B2/ja
Priority to DK01271363T priority patent/DK1345910T3/da
Priority to AU2002219174A priority patent/AU2002219174B2/en
Priority to AT01271363T priority patent/ATE430136T1/de
Priority to CNB018208665A priority patent/CN1277822C/zh
Priority to PCT/EP2001/014569 priority patent/WO2002050043A1/de
Priority to KR1020037008246A priority patent/KR100852102B1/ko
Priority to NZ526918A priority patent/NZ526918A/en
Priority to MXPA03005559A priority patent/MXPA03005559A/es
Priority to EEP200300300A priority patent/EE05244B1/xx
Priority to CZ20031930A priority patent/CZ302721B6/cs
Priority to CA002432428A priority patent/CA2432428C/en
Priority to PT01271363T priority patent/PT1345910E/pt
Priority to PL361798A priority patent/PL214798B1/pl
Priority to SI200130916T priority patent/SI1345910T1/sl
Priority to UA2003076821A priority patent/UA74614C2/uk
Priority to HU0301852A priority patent/HU228874B1/hu
Priority to SK771-2003A priority patent/SK287573B6/sk
Priority to IL15627701A priority patent/IL156277A0/xx
Priority to UY27078A priority patent/UY27078A1/es
Priority to US10/023,099 priority patent/US7019012B2/en
Priority to MYPI20015767A priority patent/MY136086A/en
Priority to AR20010105883A priority patent/AR040524A1/es
Priority to TW090131520A priority patent/TWI295992B/zh
Publication of DE10063435A1 publication Critical patent/DE10063435A1/de
Priority to ZA200304141A priority patent/ZA200304141B/en
Priority to IL156277A priority patent/IL156277A/en
Priority to NO20032726A priority patent/NO325672B1/no
Priority to BG107929A priority patent/BG66139B1/bg
Priority to US11/313,304 priority patent/US20060100223A1/en
Priority to CY20091100793T priority patent/CY1109290T1/el
Priority to US12/542,929 priority patent/USRE43431E1/en
Priority to US12/563,340 priority patent/US8586608B2/en
Priority to US12/914,003 priority patent/US20110046168A1/en
Priority to FR14C0009C priority patent/FR14C0009I2/fr
Priority to LU92370C priority patent/LU92370I2/fr
Priority to LTPA2014005C priority patent/LTC1345910I2/lt
Priority to NO2014003C priority patent/NO2014003I2/no
Priority to HUS1400005C priority patent/HUS1400005I1/hu
Priority to CY2014008C priority patent/CY2014008I2/el
Priority to BE2014C009C priority patent/BE2014C009I2/fr
Priority to NO2022028C priority patent/NO2022028I1/no
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)
DE10063435A 2000-12-20 2000-12-20 Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung Withdrawn DE10063435A1 (de)

Priority Applications (53)

Application Number Priority Date Filing Date Title
DE10063435A DE10063435A1 (de) 2000-12-20 2000-12-20 Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP01271363.2A EP1345910B9 (de) 2000-12-20 2001-12-12 Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP09158964A EP2112140A1 (de) 2000-12-20 2001-12-12 Chinazolinderivate, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
YUP-496/03A RS50860B (sr) 2000-12-20 2001-12-12 Derivati hinazolina, lekovi koji sadrže ova jedinjenja, njihova primena i postupak za njihovo pripremanje
EA200300671A EA006317B1 (ru) 2000-12-20 2001-12-12 Производные хиназолина, содержащие эти соединения лекарственные средства, их применение и способ их получения
HK04103590.4A HK1060571B (en) 2000-12-20 2001-12-12 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
DE50114874T DE50114874D1 (de) 2000-12-20 2001-12-12 Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
AU1917402A AU1917402A (en) 2000-12-20 2001-12-12 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
BRPI0116266A BRPI0116266B8 (pt) 2000-12-20 2001-12-12 "derivado de quinazolina e seu uso, bem como composição farmacêutica".
MEP-2008-595A ME02777B (me) 2000-12-20 2001-12-12 Derivati hinazolina, lekovi koii sadrže ova jedinjenja, njihova primena i postupak za njihovo pripremanje
HR20030504A HRP20030504B1 (en) 2000-12-20 2001-12-12 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
ES01271363T ES2326617T3 (es) 2000-12-20 2001-12-12 Derivados de quinazolina, medicamentos que contienen a estos compuestos, su uso y procedimiento para su preparacion.
JP2002551540A JP3827641B2 (ja) 2000-12-20 2001-12-12 キナゾリン誘導体、その医薬組成物、使用及び製法
DK01271363T DK1345910T3 (da) 2000-12-20 2001-12-12 Quinazolinderivater, lægemidler indeholdende forbindelserne, deres anvendelse og fremgangsmåde til fremstilling deraf
AU2002219174A AU2002219174B2 (en) 2000-12-20 2001-12-12 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
AT01271363T ATE430136T1 (de) 2000-12-20 2001-12-12 Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
CNB018208665A CN1277822C (zh) 2000-12-20 2001-12-12 喹唑啉衍生物,含该化合物的药物组合物,其用途及其制备方法
PCT/EP2001/014569 WO2002050043A1 (de) 2000-12-20 2001-12-12 Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
KR1020037008246A KR100852102B1 (ko) 2000-12-20 2001-12-12 퀴나졸린 유도체, 이의 제조방법 및 이를 함유하는 약제
NZ526918A NZ526918A (en) 2000-12-20 2001-12-12 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
MXPA03005559A MXPA03005559A (es) 2000-12-20 2001-12-12 Derivados de quinazolina, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion.
EEP200300300A EE05244B1 (et) 2000-12-20 2001-12-12 Kinasoliinderivaadid, neid hendeid sisaldavad ravimid, nende kasutamine ja meetod nende valmistamiseks
CZ20031930A CZ302721B6 (cs) 2000-12-20 2001-12-12 Chinazolinové deriváty
CA002432428A CA2432428C (en) 2000-12-20 2001-12-12 Quinazoline derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
PT01271363T PT1345910E (pt) 2000-12-20 2001-12-12 Derivados de quinazolina, medicamentos contendo estes compostos, sua utilização e processos para a sua preparação
PL361798A PL214798B1 (pl) 2000-12-20 2001-12-12 Pochodne chinazoliny, kompozycja farmaceutyczna je zawierajaca, ich zastosowanie i sposób ich wytwarzania
SI200130916T SI1345910T1 (sl) 2000-12-20 2001-12-12 Kinazolinski derivati, zdravila, ki vsebujejo te spojine, njihova uporaba in postopek za njihovo pripravo
UA2003076821A UA74614C2 (en) 2000-12-20 2001-12-12 Quinazoline derivatives and medicament based thereon
HU0301852A HU228874B1 (en) 2000-12-20 2001-12-12 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
SK771-2003A SK287573B6 (sk) 2000-12-20 2001-12-12 Chinazolínové deriváty, spôsob ich prípravy, farmaceutický prostriedok s ich obsahom a ich použitie
IL15627701A IL156277A0 (en) 2000-12-20 2001-12-12 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
UY27078A UY27078A1 (es) 2000-12-20 2001-12-17 Derivados de quinazolina, medicamentos que contienen estos compuestos, su empleo y procedimentos para su preparación
US10/023,099 US7019012B2 (en) 2000-12-20 2001-12-17 Quinazoline derivatives and pharmaceutical compositions containing them
MYPI20015767A MY136086A (en) 2000-12-20 2001-12-19 Quinazoline derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
AR20010105883A AR040524A1 (es) 2000-12-20 2001-12-19 Derivados de quinazolina, medicamentos que contienen estos compuestos, su empleo y procedimientos para su preparacion
TW090131520A TWI295992B (en) 2000-12-20 2001-12-19 Quinazoline derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them
ZA200304141A ZA200304141B (en) 2000-12-20 2003-05-28 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof.
IL156277A IL156277A (en) 2000-12-20 2003-06-03 Quinazoline derivatives, medicaments containing said compounds, their utilization and method for the production thereof
NO20032726A NO325672B1 (no) 2000-12-20 2003-06-16 Kinazolinderivater, medikamenter inneholdende disse forbindelser, deres anvendelse for fremstilling av legemidler og fremgangsmate for fremstilling derav
BG107929A BG66139B1 (bg) 2000-12-20 2003-06-19 Хиназолинови производни, съдържащи ги лекарствени средства, тяхното използване и метод за получаването им
US11/313,304 US20060100223A1 (en) 2000-12-20 2005-12-21 Quinazoline derivatives and pharmaceutical compositions containing them
CY20091100793T CY1109290T1 (el) 2000-12-20 2009-07-23 Παραγωγα κιναζολινης, φαρμακα που περιεχουν τις ενωσεις αυτες χρηση αυτων και μεθοδους για την παραγωγη τους
US12/542,929 USRE43431E1 (en) 2000-12-20 2009-08-18 Quinazoline derivatives and pharmaceutical compositions containing them
US12/563,340 US8586608B2 (en) 2000-12-20 2009-09-21 Quinazoline derivatives and pharmaceutical compositions containing them
US12/914,003 US20110046168A1 (en) 2000-12-20 2010-10-28 Methods of treating diseases using quinazoline derivatives and pharmaceutical compositions containing them
FR14C0009C FR14C0009I2 (fr) 2000-12-20 2014-01-30 Derives de la quinazoline, medicaments contenant ces composes, leur utilisation et leur procede de fabrication
LU92370C LU92370I2 (fr) 2000-12-20 2014-01-31 Afatinib, les tautomères, les stéréoisomères et les sels de celui-ci, des sels physiologiquement acceptables de celui-ci avec des acides ou bases organiques ou inorganiques, de préférence un sel maléate de celui-ci, et plus de préférence un sel dimaléate de celui-ci
LTPA2014005C LTC1345910I2 (lt) 2000-12-20 2014-02-06 Chinazolidino dariniai, minėtus junginius turintys vaistai, jų panaudojimas ir jų gavimo būdas
NO2014003C NO2014003I2 (no) 2000-12-20 2014-02-11 Afatinib - tautomerer, stereoisomerer og salter derav, fysiologisk akseptable salter med uorganiske eller organiske syrer eller baser, fortrinnsvis et maleatsalt derav, mer fortrinnsvis et dimaletsalt derav (patentkravene 3, 4 og 5)
HUS1400005C HUS1400005I1 (hu) 2000-12-20 2014-02-12 Kinazolinszármazékok, elõállításuk, alkalmazásuk és ezeket tartalmazó gyógyszerek
CY2014008C CY2014008I2 (el) 2000-12-20 2014-02-12 Παραγωγα κιναζολινης, φαρμακα που περιεχουν τις ενωσεις αυτες, χρηση αυτων και μεθοδους για την παραγωγη τους
BE2014C009C BE2014C009I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2000-12-20 2014-02-18
NO2022028C NO2022028I1 (no) 2000-12-20 2022-07-01 Afatinib - tautomers, stereoisomers og salts thereof - forlengelse SPC

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE10063435A DE10063435A1 (de) 2000-12-20 2000-12-20 Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
DE10063435A1 true DE10063435A1 (de) 2002-07-04

Family

ID=7667887

Family Applications (2)

Application Number Title Priority Date Filing Date
DE10063435A Withdrawn DE10063435A1 (de) 2000-12-20 2000-12-20 Chinazolinderviate,diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE50114874T Expired - Lifetime DE50114874D1 (de) 2000-12-20 2001-12-12 Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung

Family Applications After (1)

Application Number Title Priority Date Filing Date
DE50114874T Expired - Lifetime DE50114874D1 (de) 2000-12-20 2001-12-12 Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung

Country Status (39)

Country Link
EP (2) EP2112140A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
JP (1) JP3827641B2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
KR (1) KR100852102B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CN (1) CN1277822C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AR (1) AR040524A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AT (1) ATE430136T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
AU (2) AU1917402A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BE (1) BE2014C009I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BG (1) BG66139B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
BR (1) BRPI0116266B8 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CA (1) CA2432428C (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CY (2) CY1109290T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
CZ (1) CZ302721B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DE (2) DE10063435A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
DK (1) DK1345910T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EA (1) EA006317B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
EE (1) EE05244B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ES (1) ES2326617T3 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
FR (1) FR14C0009I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HR (1) HRP20030504B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
HU (2) HU228874B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
IL (2) IL156277A0 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LT (1) LTC1345910I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
LU (1) LU92370I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ME (1) ME02777B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MX (1) MXPA03005559A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
MY (1) MY136086A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NO (3) NO325672B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
NZ (1) NZ526918A (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PL (1) PL214798B1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
PT (1) PT1345910E (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
RS (1) RS50860B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SI (1) SI1345910T1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
SK (1) SK287573B6 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
TW (1) TWI295992B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UA (1) UA74614C2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
UY (1) UY27078A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
WO (1) WO2002050043A1 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)
ZA (1) ZA200304141B (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0201900A3 (en) 1999-06-21 2003-02-28 Boehringer Ingelheim Pharma Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods for the production thereof
US7019012B2 (en) 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10204462A1 (de) * 2002-02-05 2003-08-07 Boehringer Ingelheim Pharma Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
US6924285B2 (en) 2002-03-30 2005-08-02 Boehringer Ingelheim Pharma Gmbh & Co. Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
US20040044014A1 (en) 2002-04-19 2004-03-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for the preparation thereof
DE10221018A1 (de) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
PE20040945A1 (es) * 2003-02-05 2004-12-14 Warner Lambert Co Preparacion de quinazolinas substituidas
US7223749B2 (en) 2003-02-20 2007-05-29 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
DE10307165A1 (de) * 2003-02-20 2004-09-02 Boehringer Ingelheim Pharma Gmbh & Co. Kg Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
DE10334226A1 (de) * 2003-07-28 2005-02-17 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verwendung von Tyrosinkinase-Inhibitoren zur Behandlung inflammatorischer Prozesse
GB0317665D0 (en) 2003-07-29 2003-09-03 Astrazeneca Ab Qinazoline derivatives
DK1667991T3 (da) 2003-09-16 2008-08-18 Astrazeneca Ab Quinazolinderivater som tyrosinkinaseinhibitorer
US7456189B2 (en) 2003-09-30 2008-11-25 Boehringer Ingelheim International Gmbh Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
DE10349113A1 (de) 2003-10-17 2005-05-12 Boehringer Ingelheim Pharma Verfahren zur Herstellung von Aminocrotonylverbindungen
AU2005239878B9 (en) * 2004-05-06 2010-01-07 Warner-Lambert Company Llc 4-phenylamino-quinazolin-6-yl-amides
US20060035893A1 (en) 2004-08-07 2006-02-16 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
PE20060777A1 (es) 2004-12-24 2006-10-06 Boehringer Ingelheim Int Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
WO2006081741A1 (fr) * 2005-02-05 2006-08-10 Piaoyang Sun Dérivés de quinazoline ou leurs sels de qualité pharmaceutique, synthèse et applications médicales desdites substances
KR100832594B1 (ko) * 2005-11-08 2008-05-27 한미약품 주식회사 다중저해제로서의 퀴나졸린 유도체 및 이의 제조방법
EP1948180B1 (en) * 2005-11-11 2013-03-13 Boehringer Ingelheim International GmbH Combination treatment of cancer comprising egfr/her2 inhibitors
CA2833852C (en) * 2005-11-11 2014-10-21 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
WO2007085638A1 (en) * 2006-01-26 2007-08-02 Boehringer Ingelheim International Gmbh Process for preparing aminocrotonylamino-substituted quinazoline derivatives
CA2663599A1 (en) 2006-09-18 2008-03-27 Boehringer Ingelheim International Gmbh Method for treating cancer harboring egfr mutations
EP1921070A1 (de) 2006-11-10 2008-05-14 Boehringer Ingelheim Pharma GmbH & Co. KG Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
WO2008095847A1 (de) 2007-02-06 2008-08-14 Boehringer Ingelheim International Gmbh Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
KR20100111291A (ko) 2008-02-07 2010-10-14 베링거 인겔하임 인터내셔날 게엠베하 스피로사이클릭 헤테로사이클, 상기 화합물을 함유하는 약제, 이의 용도 및 이의 제조 방법
EA019183B1 (ru) 2008-05-13 2014-01-30 Астразенека Аб Фумаратная соль 4-(3-хлор-2-фторанилино)-7-метокси-6-{[1-(n-метилкарбамоилметил)пиперидин-4-ил]окси}хиназолина
PE20100252A1 (es) 2008-06-06 2010-04-12 Boehringer Ingelheim Int Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
EP2313397B1 (de) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy-substituierte heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2010054285A2 (en) 2008-11-10 2010-05-14 National Health Research Institutes Fused bicyclic and tricyclic pyrimidine compounds as tyrosine kinase inhibitors
US20120157472A1 (en) 2009-01-14 2012-06-21 Boehringer Ingelheim International Gmbh Method for treating colorectal cancer
EP2429520A1 (en) 2009-05-14 2012-03-21 Boehringer Ingelheim International GmbH New combination therapy in treatment of oncological and fibrotic diseases
WO2010130758A1 (en) * 2009-05-14 2010-11-18 Boehringer Ingelheim International Gmbh New combination therapy in treatment of cancer and fibrotic diseases
DK2451445T3 (da) 2009-07-06 2019-06-24 Boehringer Ingelheim Int Fremgangsmåde til at tørre bibw2992, dets salte og faste farmaceutiske formuleringer omfattende denne aktive ingrediens
JP2013512882A (ja) 2009-12-07 2013-04-18 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング トリプルネガティブ乳癌の治療に使用するｂｉｂｗ２９９２
US8735409B2 (en) * 2009-12-21 2014-05-27 Qiang Zhang Quinazoline derivatives
US20120107304A1 (en) 2010-04-27 2012-05-03 Boehringer Ingelheim International Gmbh Combination therapy in treatment of oncological and fibrotic diseases
EP2608792B1 (en) 2010-08-26 2017-10-11 Boehringer Ingelheim International GmbH Methods of administering an egfr inhibitor
EA024026B1 (ru) * 2010-11-25 2016-08-31 Рациофарм Гмбх Новые соли и полиморфные формы афатиниба
BR112013022552B1 (pt) 2011-03-04 2021-11-23 Newgen Therapeutics, Inc Compostos de quinazolina substituídos com alcino, seu uso, composição farmacêutica, e kit
US8828391B2 (en) 2011-05-17 2014-09-09 Boehringer Ingelheim International Gmbh Method for EGFR directed combination treatment of non-small cell lung cancer
WO2012155339A1 (zh) * 2011-05-17 2012-11-22 江苏康缘药业股份有限公司 4-苯胺-6-丁烯酰胺-7-烷醚喹唑啉衍生物及其制备方法和用途
CN102838590B (zh) * 2011-06-21 2014-07-09 苏州迈泰生物技术有限公司 氨基喹唑啉衍生物及其在制备抗恶性肿瘤药物中的用途
EP2753616A1 (en) 2011-10-06 2014-07-16 Ratiopharm GmbH Crystalline forms of afatinib di-maleate
CN103073539B (zh) * 2011-10-26 2016-05-11 齐鲁制药有限公司 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途
UA111010C2 (uk) 2012-01-17 2016-03-10 Астеллас Фарма Інк. Сполука піразинкарбоксаміду
CN103772380A (zh) * 2012-10-23 2014-05-07 杨子娇 一类治疗房角狭窄的化合物及其用途
US20150368230A1 (en) 2013-02-01 2015-12-24 Boehringer Ingelheim International Gmbh Radiolabeled quinazoline derivatives
CA2812519A1 (en) 2013-04-05 2014-10-05 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1213818A1 (zh) 2013-04-05 2016-07-15 勃林格殷格翰国际有限公司 依帕列净的治疗用途
HRP20190101T1 (hr) 2013-04-05 2019-03-08 Boehringer Ingelheim International Gmbh Terapeutske uporabe empagliflozina
US11813275B2 (en) 2013-04-05 2023-11-14 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
HK1215378A1 (zh) 2013-04-18 2016-08-26 勃林格殷格翰国际有限公司 药物组合物、治疗方法及其用途
CN103254183B (zh) * 2013-05-10 2015-11-11 苏州明锐医药科技有限公司 阿法替尼的制备方法
CN103254182A (zh) * 2013-05-10 2013-08-21 苏州明锐医药科技有限公司 一种阿法替尼的制备方法
WO2014180271A1 (zh) * 2013-05-10 2014-11-13 苏州明锐医药科技有限公司 阿法替尼及其中间体的制备方法
WO2014183560A1 (zh) * 2013-05-16 2014-11-20 苏州明锐医药科技有限公司 阿法替尼及其中间体的制备方法
CN103242303B (zh) * 2013-05-16 2015-03-25 苏州明锐医药科技有限公司 阿法替尼的制备方法
CN104513229A (zh) * 2013-09-28 2015-04-15 正大天晴药业集团股份有限公司 喹唑啉衍生物及其制备方法
CN103755688B (zh) * 2013-12-24 2015-11-18 江苏奥赛康药业股份有限公司 一种阿法替尼化合物的制备方法
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
EP3089976B1 (en) 2014-01-02 2019-08-14 Teva Pharmaceuticals International GmbH Crystalline forms of afatinib dimaleate
CN105315263B (zh) * 2014-07-30 2018-11-27 正大天晴药业集团股份有限公司 阿法替尼中间体的合成方法
EP3023421A1 (en) 2014-11-21 2016-05-25 Sandoz Ag Crystalline forms of afatinib dimaleate
CN105801568B (zh) 2015-01-15 2019-07-30 杭州普晒医药科技有限公司 阿法替尼一马来酸盐晶型及其制备方法和药物组合物
ES2775614T3 (es) 2015-03-20 2020-07-27 Chai Tai Tianqing Pharmaceutical Group Co Ltd Sales de derivado de quinazolina y método de preparación de las mismas
CN105175400B (zh) * 2015-09-29 2018-04-10 河北神威药业有限公司 一种阿法替尼中间体的制备方法
WO2017141271A1 (en) * 2016-02-17 2017-08-24 Sun Pharmaceutical Industries Ltd. Stable pharmaceutical composition of afatinib
CN106442793B (zh) * 2016-10-21 2019-05-24 河北神威药业有限公司 一种制备阿法替尼的中间体及其对映异构体的检测方法
US20180125813A1 (en) 2016-11-10 2018-05-10 Boehringer Ingelheim International Gmbh Pharmaceutical composition, methods for treating and uses thereof
TWI808958B (zh) 2017-01-25 2023-07-21 美商特普醫葯公司 涉及二芳基巨環化合物之組合療法
WO2019126136A2 (en) * 2017-12-18 2019-06-27 Sterngreene, Inc. Pyrimidine compounds useful as tyrosine kinase inhibitors
CN110437163A (zh) * 2018-05-03 2019-11-12 斯特恩格林公司 作为酪氨酸激酶抑制剂的嘧啶类化合物
WO2020068867A1 (en) 2018-09-25 2020-04-02 Black Diamond Therapeutics, Inc. Quinazoline derivatives as tyrosine kinase inhibitor, compositions, methods of making them and their use
CN109265449B (zh) * 2018-11-07 2021-11-23 沈阳工业大学 Egfr和her2双靶点酪氨酸激酶抑制剂及制备方法和用途
AU2019407426A1 (en) 2018-12-21 2021-07-22 Daiichi Sankyo Company, Limited Combination of antibody-drug conjugate and kinase inhibitor
CN109824657A (zh) * 2019-03-26 2019-05-31 石药集团中奇制药技术（石家庄）有限公司 一种二马来酸阿法替尼新晶型及其制备方法和应用
BR112022002518A2 (pt) 2019-08-15 2022-07-19 Black Diamond Therapeutics Inc Compostos de alquinila quinazolina
CN110590682A (zh) * 2019-10-14 2019-12-20 重庆医科大学 一种制备阿法替尼杂质的方法以及制备的杂质
US20210161897A1 (en) 2019-11-12 2021-06-03 Astrazeneca Ab Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer
CN114980883A (zh) 2020-01-20 2022-08-30 阿斯利康(瑞典)有限公司 用于治疗癌症的表皮生长因子受体酪氨酸激酶抑制剂
US20210369709A1 (en) 2020-05-27 2021-12-02 Astrazeneca Ab EGFR TKIs FOR USE IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER
TWI847289B (zh) * 2021-09-30 2024-07-01 大陸商北京賽特明強醫藥科技有限公司 喹唑啉類化合物、組合物及其應用
JP2025510910A (ja) 2022-03-31 2025-04-15 アストラゼネカ・アクチエボラーグ 癌の処置のための、ａｋｔ阻害剤との組み合わせにおける上皮成長因子受容体（ｅｇｆｒ）チロシンキナーゼ阻害剤
WO2023209086A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds for treating cancer
WO2023209088A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their use in the treatment of cancer
US20250214995A1 (en) 2022-04-28 2025-07-03 Astrazeneca Ab Condensed bicyclic heteroaromatic compounds and their use in the treatment of cancer
WO2023209090A1 (en) 2022-04-28 2023-11-02 Astrazeneca Ab Bicyclic heteroaromatic compounds and their application in the treatment of cancer
WO2024002938A1 (en) 2022-06-27 2024-01-04 Astrazeneca Ab Combinations involving epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of cancer

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3370340B2 (ja) * 1996-04-12 2003-01-27 ワーナー―ランバート・コンパニー チロシンキナーゼの不可逆的阻害剤
ZA986729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA986732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
DE19908567A1 (de) * 1999-02-27 2000-08-31 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE19911366A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
HUP0301132A3 (en) * 1999-02-27 2004-03-29 Boehringer Ingelheim Pharma 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases, process for their preparation their use and pharmaceutical compositions containing them
DE19911509A1 (de) * 1999-03-15 2000-09-21 Boehringer Ingelheim Pharma Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
HUP0201900A3 (en) * 1999-06-21 2003-02-28 Boehringer Ingelheim Pharma Bicyclic heterocycles, pharmaceutical compositions containing them, their use and methods for the production thereof
DE50111799D1 (de) * 2000-04-08 2007-02-15 Boehringer Ingelheim Pharma Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung

Also Published As

Publication number Publication date
KR20030071787A (ko) 2003-09-06
CY1109290T1 (el) 2014-07-02
YU49603A (sh) 2006-05-25
IL156277A (en) 2009-12-24
MY136086A (en) 2008-08-29
UA74614C2 (en) 2006-01-16
UY27078A1 (es) 2002-07-31
NO325672B1 (no) 2008-07-07
AU2002219174B2 (en) 2007-09-06
CN1481370A (zh) 2004-03-10
EE05244B1 (et) 2009-12-15
MEP59508A (en) 2011-05-10
HRP20030504A2 (en) 2005-06-30
BG66139B1 (bg) 2011-07-29
CZ302721B6 (cs) 2011-09-21
ES2326617T3 (es) 2009-10-16
SK7712003A3 (en) 2003-10-07
EP1345910B1 (de) 2009-04-29
PT1345910E (pt) 2009-07-14
BE2014C009I2 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2021-02-04
CY2014008I2 (el) 2015-12-09
AR040524A1 (es) 2005-04-13
DK1345910T3 (da) 2009-07-20
NO20032726L (no) 2003-06-16
NO2022028I1 (no) 2022-07-01
ZA200304141B (en) 2004-04-15
IL156277A0 (en) 2004-01-04
EE200300300A (et) 2003-10-15
BG107929A (bg) 2005-01-31
LTC1345910I2 (lt) 2022-06-10
EP1345910A1 (de) 2003-09-24
JP2004516283A (ja) 2004-06-03
EP1345910B9 (de) 2014-06-04
EA006317B1 (ru) 2005-10-27
HRP20030504B1 (en) 2011-09-30
CY2014008I1 (el) 2014-07-02
JP3827641B2 (ja) 2006-09-27
TWI295992B (en) 2008-04-21
BRPI0116266B8 (pt) 2021-07-27
NO2014003I2 (no) 2015-10-19
CA2432428C (en) 2009-09-01
HUP0301852A2 (hu) 2003-09-29
BRPI0116266B1 (pt) 2017-10-31
NO20032726D0 (no) 2003-06-16
LU92370I9 (GUID-C5D7CC26-194C-43D0-91A1-9AE8C70A9BFF.html) 2019-01-17
FR14C0009I1 (fr) 2014-03-07
HK1060571A1 (en) 2004-08-13
PL361798A1 (en) 2004-10-04
CA2432428A1 (en) 2002-06-27
SI1345910T1 (sl) 2009-08-31
SK287573B6 (sk) 2011-03-04
EA200300671A1 (ru) 2004-06-24
AU1917402A (en) 2002-07-01
PL214798B1 (pl) 2013-09-30
HUP0301852A3 (en) 2008-03-28
NO2014003I1 (no) 2014-06-02
RS50860B (sr) 2010-08-31
FR14C0009I2 (fr) 2014-11-14
WO2002050043A1 (de) 2002-06-27
ME02777B (me) 2011-10-10
DE50114874D1 (de) 2009-06-10
NZ526918A (en) 2006-11-30
LU92370I2 (fr) 2014-03-31
HU228874B1 (en) 2013-06-28
HUS1400005I1 (hu) 2017-08-28
EP2112140A1 (de) 2009-10-28
CN1277822C (zh) 2006-10-04
BR0116266A (pt) 2004-02-17
KR100852102B1 (ko) 2008-08-13
CZ20031930A3 (cs) 2003-10-15
LTPA2014005I1 (lt) 2022-05-25
ATE430136T1 (de) 2009-05-15
ES2326617T9 (es) 2014-09-10
MXPA03005559A (es) 2004-10-14

Similar Documents

Publication Publication Date Title
EP1345910B9 (de) Chinazolinderivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP1731511B1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP1315718B1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP1315720B1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
US20020173509A1 (en) Quinazoline derivatives and phamaceutical compositions containing them
WO2002018351A1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und vefahren zu ihrer herstellung
EP1597240B1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, ihre verwendung und verfahren zu ihrer herstellung
WO2002018373A1 (de) Chinazolin derivate, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
WO2001077104A1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
EP1966189A1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE10217689A1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, ihre Verwendung und Verfahren zu ihrer Herstellung
DE10326186A1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
EP2118075A1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE10214412A1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2002018375A1 (de) Chinazoline, diese verbindungen enthaltende als tyrosinkinase inhibitoren wirksame arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE10017539A1 (de) Bicyclische Heterocyclen, diese Verbingungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
WO2007101782A1 (de) Bicyclische heterocyclen, diese verbindungen enthaltende arzneimittel, deren verwendung und verfahren zu ihrer herstellung
DE10023085A1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10231711A1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung
DE10040525A1 (de) Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstellung

Legal Events

Date Code Title Description
8127 New person/name/address of the applicant

Owner name: BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG, 55218 IN

8110 Request for examination paragraph 44
R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee

Effective date: 20110701